'Wow, what a year': Dorset firm achieves record-breaking recycling
An organic recycling and renewable energy company produced more green energy than ever in 2024.
Parley-based Eco Sustainable Solutions said its energy assets were "the true stars" of the year, generating enough energy to power more than 6,600 homes.
In a record-breaking year, Eco recycled 61,191 tonnes of green waste, 36,960 tonnes of food waste, 51,462 tonnes of wood waste, 57,930 tonnes of excavated soils and 28,903 tonnes of sweet sweepings.
This recycling and recovery effort prevented 116,434 tonnes of carbon dioxide from entering the atmosphere by diverting waste from landfill.
READ MORE: Hard plastic not being recycled in BCP but going to landfill
Justin Dampney, Managing Director, Eco Sustainable Solutions Ltd (Image: Eco Sustainable Solutions) Other highlights in Eco's annual sustainability report included the beginning of work on a new anaerobic digestion (AD) facility at its Parley Eco Park, set to be operational this October.
The plant is expected to generate enough energy to heat more than 7,000 homes.
The company also exceeded a five per cent carbon efficiency target by trialling alternatives to traditional diesel.
Managing director Justin Dampney said: "Wow, what a year 2024 has been for all of us at Eco.
"I'm incredibly proud of the initiatives, innovations and achievements we've accomplished."
Founded in 1995, Eco Sustainable Solutions has an annual turnover of £17 million and employs 52 people.
It has sites at Weymouth, Parley and Piddlehinton.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
ANGLE plc Announces Novel Discoveries Into the Biology of Cancer
PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer Academic and translational research is the driving force behind the pipeline of next generation cancer therapeutics GUILDFORD, SURREY / / June 10, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of three new peer-reviewed publications reporting first-in-class research into the biology of cancer and potential therapeutic targets using the Company's Parsortix system. Tumour cell release during surgery for prostate cancer1Professor Klaus Pantel and researchers from the University Medical Center Hamburg-Eppendorf published an article in the Journal of Experimental & Clinical Cancer Research, investigating tumour cell release into the local tumour vein and peripheral veins during surgery in early-stage prostate cancer patients. The study provides first evidence for substantial release of healthy and cancerous cells into the blood during prostatectomy surgery. This research opens a new avenue for the Parsortix system to study the important and under-investigated biology of tumour cell release during surgery to understand the risk they pose to patients, and for the development of strategies to minimise the spread of cancer. Tumour cell release during surgery for ovarian cancer2Professor John O'Leary and researchers from Trinity College Dublin have published similar findings in the European Journal of Surgical Oncology, investigating CTC enrichment from the local tumour vein and peripheral veins during surgery in rare epithelial ovarian carcinomas. They reported higher yields of CTCs and CTC clusters in the local tumour vein when compared to peripheral veins. The study also reported that CTCs were detected in early-stage patients, highlighting the risk of early tumour cell dissemination driving cancer progression even in the initial stages of disease. Overall, the authors state that assessing tumour cell release during surgery is a novel strategy to study the biology of this rare disease. Mechanical conditioning & metastatic implications3Professor Julie Lang and researchers from the Cleveland Clinic have published an article in Cancers, investigating biomechanical adaptions of cells that are associated with increased metastatic potential in breast cancer patients. They studied the expression of 1004 genes via RNA-sequencing that reflect how cancer cells respond to a stiff extracellular matrix described as a mechanical conditioning score. The Parsortix system was utilised to enrich and harvest CTCs from a metastatic cohort of breast cancer patients for analysis and compared these to primary and metastatic tissue. The study analysed RNA from CTCs rather than ctDNA to provide insight into gene expression. They state that: 'When analyzing shed ctDNA, there is no insight into gene expression, but rather only the presence of tumor-specific mutations, which is not directly reflective of dynamic tumor gene expression. In fact, only a very small percentage of DNA mutations are expressed, which is why circulating tumor DNA and RNA from CTCs are not parallel assays'. The study reported that the mechanical conditioning score increases progressively through the metastatic cascade (from the primary tumour to CTCs to the metastatic site) and is associated with increased metastatic potential. These are new insights into the biology of metastatic progression and may guide treatment selection with anti-fibrotic drugs. Overall, these publications further underscore the role of the Parsortix system in helping to advance our understanding of the biology of cancer which will ultimately advance oncology drug discovery and development. Already ANGLE's technology has enabled breakthrough research in a number of areas including the metastatic potential of CTC clusters, new potential biomarkers and a novel drug class. Academic and translational research discoveries made possible by the Parsortix system, have the potential to feed the pipeline of next generation personalised cancer diagnostics and therapeutics, as pharma companies increasingly collaborate with academia4. ANGLE's Chief Scientific Officer, Karen Miller, commented:"We are proud to see ANGLE's technology increasingly being exploited to make novel discoveries into the biology of cancer, which may eventually result in new treatment strategies. With advancing analytical capabilities beginning to realise the vast potential of the circulating tumour cell for its wealth of multiomic information, this contribution to the oncology pipeline will continue to grow. We congratulate these key opinion leaders on their outstanding work, and we look forward to more exciting discoveries in the future." 1. Emurlai, G. et al. Comparative analysis of circulating tumor cells in prostatic plexus and peripheral blood of patients undergoing prostatectomy. J. Exp. Clin. Cancer Res. 44, 143 (2025). 2. Lewis, F. et al. A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas. Eur. J. Surg. Oncol. 51, (2025). 3. Mouneimne, G. et al. Mechanical Conditioning (MeCo) Score Progressively Increases Through the Metastatic Cascade in Breast Cancer via Circulating Tumor Cells. Cancers 17, 1632 (2025). 4. For further information: ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Research Use Only. Not for use in diagnostic procedures. For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays. Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product: The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: ANGLE plc View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
36 minutes ago
- Bloomberg
UK Employment Drops Most Since 2020 and Wage Growth Cools
UK wages grew at the slowest pace for seven months and employment plunged, as the labor market continued to ease after Prime Minister Keir Starmer's government ramped up the cost of hiring. Pay growth excluding bonuses eased to 5.2% in the three months through April, the least since the third quarter of last year, the Office for National Statistics said Tuesday. Economists had expected 5.3% on average. Private-sector wage growth — the measure watched most closely by the Bank of England — cooled to slowed to 5.1% from 5.5%. Vacancies fell in the three months through May.
Yahoo
37 minutes ago
- Yahoo
EMV Capital Full Year 2024 Earnings: UK£0.13 loss per share (vs UK£0.11 loss in FY 2023)
Revenue: UK£2.45m (up 70% from FY 2023). Net loss: UK£3.06m (loss widened by 16% from FY 2023). UK£0.13 loss per share (further deteriorated from UK£0.11 loss in FY 2023). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period The primary driver behind last 12 months revenue was the United Kingdom segment contributing a total revenue of UK£2.08m (85% of total revenue). The largest operating expense was General & Administrative costs, amounting to UK£4.07m (79% of total expenses). Explore how EMVC's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 6.1% growth forecast for the Medical Equipment industry in the United Kingdom. Performance of the British Medical Equipment industry. The company's shares are up 11% from a week ago. You still need to take note of risks, for example - EMV Capital has 4 warning signs (and 2 which are concerning) we think you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
